{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:41:10Z","timestamp":1794638470291,"version":"4.9.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>\u03b3\u03b4 T cells represent key players in immune surveillance after T-cell receptor \u03b1\/\u03b2 (\u03b1\u03b2)\/CD19-depleted HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Although encouraging data are available on the impact of V\u03b42-targeting therapy in improving HSCT clinical outcomes, their role in providing antimicrobial immunity is largely unexplored. This study aimed to investigate the antiviral protective profile of V\u03b42\u00a0T cells in pediatric patients given haplo-HSCT. The characterization of \u03b3\u03b4 T cells was performed in pediatric recipients (n\u00a0=\u00a026) in the donor graft and at 30, 60, and 120\u00a0days after haplo-HSCT. The antiviral activity of V\u03b42\u00a0T cells and the cytomegalovirus\u00a0(CMV)-specific \u03b1\u03b2 T-cell immunity was analyzed. Early after HSCT, V\u03b42\u00a0T cells was significantly higher in patients who did not experience viral reactivation (No-VR) than in patients with CMV reactivation. Interestingly, this difference was already present in the grafts. Clustering analysis identified a protective subset of V\u03b42\u00a0T cells in patients with No-VR, expressing CD16, NKG2D, and CD107a, and producing Th1 cytokines. This subset directly correlated with interleukin-15 and inversely with the CMV DNA level. Stimulated V\u03b42\u00a0T cells inhibit CMV replication, acquired CD86\/HLA-DR molecules, induced HLA-DR on monocytes, and improved the \u03b1\u03b2 CMV\u2013specific T-cell response. Altogether, these results identify an antiviral protective profile displayed by V\u03b42\u00a0T cells early after HSCT, and define their ability to inhibit CMV replication, to induce antigen-presenting cell maturation and to improve \u03b1\u03b2 virus\u2013specific T-cell response, opening a new application of V\u03b42-targeting immunotherapy after HSCT, adding the antiviral to the antitumor potential.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013902","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T22:30:31Z","timestamp":1733265031000},"page":"990-1002","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Antiviral potential of V\u03b42\u00a0T cells in children given TCR \u03b1\u03b2\/CD19 cell-depleted HLA-haploidentical HSCT"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1747-2245","authenticated-orcid":false,"given":"Veronica","family":"Bordoni","sequence":"first","affiliation":[{"name":"1Research Area of Hematology and Oncology, Unit of Pathogen Specific Immunity, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-3398","authenticated-orcid":false,"given":"Federica","family":"Guarracino","sequence":"additional","affiliation":[{"name":"1Research Area of Hematology and Oncology, Unit of Pathogen Specific Immunity, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-2924","authenticated-orcid":false,"given":"Federica","family":"Galaverna","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9028-7767","authenticated-orcid":false,"given":"Valentina","family":"Bertaina","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6293-4314","authenticated-orcid":false,"given":"Giuseppina","family":"Li Pira","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rosichini","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pitisci","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Matusali","sequence":"additional","affiliation":[{"name":"3Lazzaro Spallanzani National Institute for Infectious Diseases, Laboratory of Virology\u2013IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Maggi","sequence":"additional","affiliation":[{"name":"3Lazzaro Spallanzani National Institute for Infectious Diseases, Laboratory of Virology\u2013IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8383-0453","authenticated-orcid":false,"given":"Enrico","family":"Velardi","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-4046","authenticated-orcid":false,"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"2Research Area of Hematology and Oncology, Cell and Gene Therapy, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"},{"name":"4Department of Maternal and Child Health, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-0927","authenticated-orcid":false,"given":"Chiara","family":"Agrati","sequence":"additional","affiliation":[{"name":"1Research Area of Hematology and Oncology, Unit of Pathogen Specific Immunity, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"17","key":"2025032513474148100_bib1","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1182\/blood-2009-03-207001","article-title":"Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group","volume":"115","author":"Klingebiel","year":"2010","journal-title":"Blood"},{"key":"2025032513474148100_bib2","doi-asserted-by":"crossref","first-page":"746221","DOI":"10.3389\/fimmu.2021.746221","article-title":"Recent developments in haploidentical hematopoietic cell transplantation: therapy and complications","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"2025032513474148100_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hemonc.2017.05.001","article-title":"Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation","volume":"10","author":"Camargo","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"2025032513474148100_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/315193","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr","year":"2000","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"2025032513474148100_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"20","key":"2025032513474148100_bib6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2025032513474148100_bib7","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2025032513474148100_bib8","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","article-title":"Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation","volume":"102","author":"Hakki","year":"2003","journal-title":"Blood"},{"issue":"19","key":"2025032513474148100_bib9","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032513474148100_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025032513474148100_bib11","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1182\/blood-2002-05-1387","article-title":"Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T-cells","volume":"100","author":"Ozdemir","year":"2002","journal-title":"Blood"},{"issue":"1-2","key":"2025032513474148100_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imlet.2013.09.027","article-title":"Negative depletion of \u03b1\/\u03b2+ T-cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation","volume":"155","author":"Locatelli","year":"2013","journal-title":"Immunol Lett"},{"issue":"5","key":"2025032513474148100_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2025032513474148100_bib14","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/bloodadvances.2019000682","article-title":"Impact of \u03b3\u03b4 T-cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"3","author":"Arruda","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2025032513474148100_bib15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2018.02.023","article-title":"Early reconstitution of NK and \u03b3\u03b4 T-cells and its implication for the design of post-transplant immunotherapy","volume":"24","author":"de Witte","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2025032513474148100_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"\u03b3\u03b4 T-cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2025032513474148100_bib17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2008-01-136713","article-title":"Long-term expansion of effector\/memory Vdelta2-gammadelta T-cells is a specific blood signature of CMV infection","volume":"112","author":"Pitard","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2025032513474148100_bib18","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2010-01-255166","article-title":"The role of V\u03b42-negative gammadelta T-cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation","volume":"116","author":"Knight","year":"2010","journal-title":"Blood"},{"key":"2025032513474148100_bib19","doi-asserted-by":"crossref","first-page":"1397483","DOI":"10.3389\/fimmu.2024.1397483","article-title":"Expansion of effector memory V\u03b42neg \u03b3\u03b4 T-cells associates with cytomegalovirus reactivation in allogeneic stem cell transplant recipients","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"2025032513474148100_bib20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/imm.13542","article-title":"Distinct activities of V\u03b41+ T-cells upon different cytomegalovirus reactivation status after haematopoietic transplantation","volume":"167","author":"Liu","year":"2022","journal-title":"Immunology"},{"issue":"35","key":"2025032513474148100_bib21","doi-asserted-by":"crossref","first-page":"E7311","DOI":"10.1073\/pnas.1707547114","article-title":"Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on V\u03b39V\u03b42\u00a0T cell activation","volume":"114","author":"Gu","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025032513474148100_bib22","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","article-title":"Human V\u03b39V\u03b42 T-cells specifically recognize and kill acute myeloid leukemic blasts","volume":"188","author":"Gertner-Dardenne","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2025032513474148100_bib23","doi-asserted-by":"crossref","first-page":"e23304","DOI":"10.4161\/onci.23304","article-title":"Human V\u03b42 versus non-V\u03b42 \u03b3\u03b4 T-cells in antitumor immunity","volume":"2","author":"Kabelitz","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025032513474148100_bib24","doi-asserted-by":"crossref","first-page":"928441","DOI":"10.3389\/fimmu.2022.928441","article-title":"Role of V\u03b39v\u03b42\u00a0T lymphocytes in infectious diseases","volume":"13","author":"Gay","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"2025032513474148100_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","article-title":"Targeted activation of human V\u03b39V\u03b42-T-cells controls epstein-barr virus-induced B cell lymphoproliferative disease","volume":"26","author":"Xiang","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"2025032513474148100_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00262-012-1368-4","article-title":"Zoledronic acid-induced expansion of \u03b3\u03b4 T-cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells","volume":"62","author":"Sugie","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"616","key":"2025032513474148100_bib27","doi-asserted-by":"crossref","first-page":"eabj0835","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42\u00a0T cell-mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"2025032513474148100_bib28","doi-asserted-by":"crossref","first-page":"e1216291","DOI":"10.1080\/2162402X.2016.1216291","article-title":"Zoledronic acid boosts \u03b3\u03b4 T-cell activity in children receiving \u03b1\u03b2+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor","volume":"6","author":"Bertaina","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025032513474148100_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fimmu.2020.00699","article-title":"Immune modulation properties of zoledronic acid on TcR\u03b3\u03b4 T-lymphocytes after TcR\u03b3\u03b4\/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia","volume":"11","author":"Merli","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"2025032513474148100_bib30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.2023021336","article-title":"TCR\u03b3\u03b4\/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis","volume":"143","author":"Merli","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025032513474148100_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/bloodadvances.2021005628","article-title":"TCR\u03b1\u03b2\/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders","volume":"6","author":"Merli","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2025032513474148100_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"issue":"6","key":"2025032513474148100_bib33","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.4049\/jimmunol.0901085","article-title":"Specific requirements for Vgamma9Vdelta2\u00a0T cell stimulation by a natural adenylated phosphoantigen","volume":"183","author":"Vantourout","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"2025032513474148100_bib34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/cyto.a.20549","article-title":"How many events is enough? Are you positive?","volume":"73","author":"Roederer","year":"2008","journal-title":"Cytometry A"},{"issue":"15","key":"2025032513474148100_bib35","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2014-09-599423","article-title":"\u03b3\u03b4 T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-\u03b1\u03b2+\/CD19+ lymphocytes","volume":"125","author":"Airoldi","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2025032513474148100_bib36","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.4049\/jimmunol.1002514","article-title":"Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V\u03b39V\u03b42 T-cells, \u03b1\u03b2 CD8+ T-cells, regulatory T-cells, and dendritic cells","volume":"187","author":"Castella","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2025032513474148100_bib37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"\u03b3\u03b4 T-cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2025032513474148100_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T-cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2025032513474148100_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.micinf.2004.12.009","article-title":"Antiviral reactivities of \u03b3\u03b4 T cells","volume":"7","author":"Poccia","year":"2005","journal-title":"Microbes Infect"},{"issue":"7","key":"2025032513474148100_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41423-020-0473-0","article-title":"More bricks in the wall against SARS-CoV-2 infection: involvement of \u03b39\u03b42 T-cells","volume":"17","author":"Rijkers","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"2025032513474148100_bib41","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/bmt.2010.13","article-title":"Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse","volume":"45","author":"Thiant","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2025032513474148100_bib42","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3389\/fimmu.2020.01868","article-title":"Expansion with IL-15 increases cytotoxicity of V\u03b39V\u03b42 T-cells and is associated with higher levels of cytotoxic molecules and T-bet","volume":"11","author":"Aehnlich","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"2025032513474148100_bib43","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2004-01-0331","article-title":"FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways","volume":"104","author":"Angelini","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2025032513474148100_bib44","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in\u00a0vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"2025032513474148100_bib45","doi-asserted-by":"crossref","first-page":"1275904","DOI":"10.3389\/fimmu.2023.1275904","article-title":"Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy","volume":"14","author":"Fantini","year":"2023","journal-title":"Front Immunol"},{"key":"2025032513474148100_bib46","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.15.23287332","article-title":"ADCC-activating antibodies correlate with protection against congenital human cytomegalovirus infection","author":"Semmes","year":"17  2023","journal-title":"medRxiv"},{"key":"2025032513474148100_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fimmu.2015.00003","article-title":"Direct and indirect effects of cytomegalovirus-induced \u03b3\u03b4 T-cells after Kidney Transplantation","volume":"6","author":"Couzi","year":"2015","journal-title":"Front Immunol"},{"key":"2025032513474148100_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fimmu.2018.00441","article-title":"NKG2D: a master regulator of immune cell responsiveness","volume":"9","author":"Wensveen","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"2025032513474148100_bib49","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/cells9061433","article-title":"An update on the molecular basis of phosphoantigen recognition by V\u03b39V\u03b42 T-cells","volume":"9","author":"Herrmann","year":"2020","journal-title":"Cells"},{"key":"2025032513474148100_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coviro.2014.03.006","article-title":"Interferon\u2013stimulated genes: roles in viral pathogenesis","volume":"6","author":"Schoggins","year":"2014","journal-title":"Curr Opin Virol"},{"key":"2025032513474148100_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-422X-2-14","article-title":"Synergistic inhibition of human cytomegalovirus replication by interferon-alpha\/beta and interferon-gamma","volume":"2","author":"Sainz","year":"2005","journal-title":"Virol J"},{"issue":"5732","key":"2025032513474148100_bib52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human gammadelta T-cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"issue":"12","key":"2025032513474148100_bib53","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nri1245","article-title":"T-cell-antigen recognition and the immunological synapse","volume":"3","author":"Huppa","year":"2003","journal-title":"Nat Rev Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/990\/2357071\/blooda_adv-2024-013902-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/990\/2357071\/blooda_adv-2024-013902-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:30:48Z","timestamp":1742949048000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/990\/534300\/Antiviral-potential-of-V-2-T-cells-in-children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013902","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}